A5048794053- Acute Myeloid Leukemia Research
- Erythropoietin and Anemia Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Hemoglobinopathies and Related Disorders
- Hematological disorders and diagnostics
- Chronic Lymphocytic Leukemia Research
- Erythrocyte Function and Pathophysiology
- Blood groups and transfusion
- Hematopoietic Stem Cell Transplantation
- Neutropenia and Cancer Infections
- Bone and Joint Diseases
- Pharmacological Effects and Toxicity Studies
- Lymphoma Diagnosis and Treatment
- Blood disorders and treatments
- Complement system in diseases
- Chronic Myeloid Leukemia Treatments
- Platelet Disorders and Treatments
- Iron Metabolism and Disorders
- Dialysis and Renal Disease Management
- Acute Lymphoblastic Leukemia research
- PARP inhibition in cancer therapy
- Protein Degradation and Inhibitors
- Pneumocystis jirovecii pneumonia detection and treatment
- Immune Cell Function and Interaction
Tel Aviv Sourasky Medical Center
2016-2025
Tel Aviv University
2016-2025
Academic College of Tel Aviv-Yafo
2010-2025
Marien Hospital Düsseldorf
2016
Heinrich Heine University Düsseldorf
2016
University of Pavol Jozef Šafárik
2015
Georgetown University
2006
Rabin Medical Center
1985-2005
National Cancer Institute
2001
Weizmann Institute of Science
2001
This international phase III, randomized, placebo-controlled, double-blind study assessed the efficacy and safety of lenalidomide in RBC transfusion-dependent patients with International Prognostic Scoring System lower-risk non-del(5q) myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents.In total, 239 were randomly assigned (2:1) treatment (n = 160) placebo 79) once per day (on 28-day cycles). The primary end point was rate transfusion independence (TI)...
Del(5q) myelodysplastic syndromes defined by the International Prognostic Scoring System as low- or intermediate-1-risk (lower-risk) are considered to have an indolent course; however, recent data identified a subgroup of these patients with more aggressive disease and poorer outcomes. Using deep sequencing technology, we previously demonstrated that 18% lower-risk del(5q) carry TP53 mutated subclones rendering them at higher risk progression. In this study, bone marrow biopsies from 85...
Erythropoietin (EPO) primarily regulates red blood cell formation, and EPO serum levels are increased on hypoxic stress (e.g., anemia altitude). In addition to anemia, recent discoveries suggest new therapeutic indications for EPO, unrelated erythropoiesis. We investigated the skeletal role of using several models overexpression (Tg6 mice) administration (intermittent/continuous, high/low doses) in adult C57Bl6 female mice. Using microcomputed tomography, histology, markers, we found that...
In myelodysplastic syndromes (MDS), health-related quality of life (HRQoL) represents a relevant patient-reported outcome, which is essential in individualized therapy planning. Prospective data on HRQoL lower-risk MDS remain rare. We assessed HRQOL by EQ-5D questionnaire at initial diagnosis 1690 consecutive IPSS-Low/Int-1 patients from the European LeukemiaNet Registry. Impairments were compared with age- and sex-matched EuroQol Group norms. A significant proportion reported...
Summary Multiple myeloma (MM) patients are at excess risk for clinically significant COVID19 infection. BNT162b2 mRNA (BNT162b2) vaccine provides effective protection against the general population, yet its effect in MM may be compromised due to disease and therapy‐related factors was not evaluated. This single‐centre prospective study included tested serological response 14–21 days post second vaccine. Vaccinated healthy volunteers served as controls. In all, 171 patients, median age 70...
Treatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating agent, in International Prognostic Scoring System LR-MDS and RBC transfusion-dependent anemia thrombocytopenia.Patients were randomly assigned 1:1 to 300-mg or placebo 21 days/28-day cycle. The primary end point was transfusion independence (TI).Two hundred sixteen received (n = 107) 109). median age 74...
Recombinant human erythropoietin (rHuEpo) has been used successfully in the treatment of cancer-related anemia. Clinical observations with several patients multiple-myeloma treated rHuEpo shown, addition to improved quality life, a longer survival than expected, considering poor prognostic features these patients. Based on observations, we evaluated potential biological effects course tumor progression by using murine myeloma models (MOPC-315-IgAlambda(2) and 5T33 MM-IgG(2b)). Here report...
Our original demonstration of immunomodulatory effects erythropoietin in multiple myeloma led us to the search for cells immune system that are direct targets erythropoietin. The finding lymphocytes do not express receptors hypothesis other act as and thus mediate has on dendritic question whether macrophages target erythropoietin.The were investigated both in-vivo in-vitro. studies performed splenic inflammatory peritoneal macrophages, comparing recombinant human erythropoietin-treated...
Abstract Anemia is the predominant cytopenia in myelodysplastic syndromes (MDS) and treatment options are limited. Roxadustat a hypoxia‐inducible factor prolyl hydroxylase inhibitor approved for of anemia chronic kidney disease UK, EU, China, Japan, South Korea, Chile. MATTERHORN phase 3, randomized, double‐blind, placebo‐controlled study to assess efficacy safety roxadustat lower risk‐MDS. Eligible patients had baseline serum erythropoietin ≤ 400 mIU/mL, low packed RBC transfusion burden....
Abstract In patients with lower‐risk myelodysplastic syndromes/neoplasms (MDS), response to first‐line therapy is limited and transient. The MATTERHORN randomized, double‐blind, phase 3 trial evaluated roxadustat versus placebo for transfusion‐dependent, MDS. Eligible had very low‐, or intermediate‐risk MDS without prior erythropoiesis‐stimulating agent treatment, a transfusion burden of 1–4 packed red blood cell (pRBC) units every 8 weeks (Q8W). Patients were randomized (3:2) oral (2.5...
The temporal sequence of expression human globin genes during development suggests precise regulation these genes. Recent studies have characterized a number DNA sequences within or flanking the beta-globin gene which are important in its and several proteins bind to been identified. We found two 5' gene. One proteins, we designate BP1, binds sequences, one between -550 -527 bp relative cap site, other -302 -294 bp. A second protein, BP2, -275 -263 binding sites for both BP1 BP2 regions...
Erythropoietin (EPO) regulates proliferation and differentiation of erythroid precursor cells into erythrocytes. The last decade has revealed non-renal sites EPO production extrahematopoietic expression the receptor, thus suggesting that pleiotropic functions. Here, we addressed interplay between EPO/glucose metabolism/body weight by employing a panel relevant experimental murine models. models focused on situations increased levels, including EPO-injected C57BL/6 BALB/c mice, as well...
Context Medical school admissions traditionally rely heavily on cognitive variables, with non-cognitive measures assessed through interviews only. In recognition of the unsatisfactory reliability and validity traditional interviews, medical schools are increasingly exploring alternative approaches that can provide improved candidates’ personal interpersonal qualities. Methods An innovative assessment centre (MOR [Hebrew acronym for ‘selection medicine’]) was designed to measure attributes....
Hypomethylating agents have become the standard therapy for patients with high‐risk myelodysplastic syndrome ( MDS ). In Israel, azacitidine AZA ) is routinely used. Yet, infectious complications are common during therapy. The current study was aimed to evaluate incidence and predisposing risk factors infections in ‐treated patients. This retrospective included treated 18 Israeli medical institutions between 2008 2011. Data on 184 [157 27 acute myeloid leukemia AML )], a median age of 71.6...
Progression-free survival (PFS) of patients with lower-risk myelodysplastic syndromes (MDS) treated red blood cell transfusions is usually reduced, but it unclear whether transfusion dose density an independent prognostic factor. The European MDS Registry collects prospective data at 6-monthly intervals from newly diagnosed in 16 countries and Israel. Data on the - cumulative received end each interval divided by time since beginning which first was were analyzed using proportional hazards...
Iron overload due to red blood cell (RBC) transfusions is associated with morbidity and mortality in lower-risk myelodysplastic syndrome (MDS) patients. Many studies have suggested improved survival after iron chelation therapy (ICT), but valid data are limited. The aim of this study was assess the effect ICT on overall hematologic improvement MDS patients European registry. We compared chelated a contemporary, non-chelated control group within registry, that met eligibility criteria for...